dc.contributor.author | Monk, BJ | |
dc.contributor.author | Smith, G | |
dc.contributor.author | Lima, J | |
dc.contributor.author | Long, GH | |
dc.contributor.author | Alam, N | |
dc.contributor.author | Nakamura, H | |
dc.contributor.author | Meulendijks, D | |
dc.contributor.author | Ghiorghiu, D | |
dc.contributor.author | Banerjee, S | |
dc.date.accessioned | 2022-04-27T12:30:23Z | |
dc.date.available | 2022-04-27T12:30:23Z | |
dc.identifier.citation | Gynecologic oncology, 2022, 164 (2), pp. 325 - 332 | en |
dc.identifier.issn | 0090-8258 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5103 | |
dc.identifier.eissn | 1095-6859 | en_US |
dc.identifier.eissn | 1095-6859 | |
dc.identifier.doi | 10.1016/j.ygyno.2021.12.008 | en_US |
dc.identifier.doi | 10.1016/j.ygyno.2021.12.008 | |
dc.description.abstract | <h4>Objectives</h4>To characterize clinical outcomes of women with advanced/recurrent endometrial cancer (AEC) in routine practice using electronic health records from a real-world database.<h4>Methods</h4>Adult women diagnosed with AEC (stage III/IV, or early stage with locoregional/distant recurrence) between January 1, 2013 and September 30, 2020, inclusive, were eligible provided they received platinum-based chemotherapy at any time following diagnosis and had ≥2 clinical visits. Follow-up was from initiation of systemic treatment after advanced diagnosis (index) until March 30, 2021, last available follow-up, or death, whichever occurred first. Outcomes, by histological subtype, included Kaplan-Meier estimates of overall survival (OS) and time to first subsequent therapy or death (TFST).<h4>Results</h4>Of the 2202 women with AEC, most were treated in a community setting (82.7%) and presented with stage III/IV disease at initial diagnosis (74.0%). The proportion with endometrioid carcinoma, uterine serous carcinoma (USC), and other AEC subtypes was 59.8%, 25.0%, and 15.2%, respectively. The most common first systemic treatment following advanced/recurrent diagnosis was platinum-based combination chemotherapy (82.0%). Median OS (95% CI) from initiation of first systemic treatment was shorter with USC (31.3 [27.7-34.3] months) and other AECs (29.4 [21.4-43.9] months) versus endometrioid carcinoma (70.8 [60.5-83.2] months). Similar results were observed for TFST. Black/African American women had worse OS and TFST than white women.<h4>Conclusions</h4>Women with AEC had poor survival outcomes, demonstrating the requirement for more effective therapies. To our knowledge, this is the most comprehensive evaluation of contemporary treatment of AEC delivered in a community setting to date. | en_US |
dc.format | Print-Electronic | en_US |
dc.format.extent | 325 - 332 | en_US |
dc.language | eng | en_US |
dc.language.iso | eng | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en |
dc.subject | Humans | en_US |
dc.subject | Carcinoma, Endometrioid | en_US |
dc.subject | Neoplasms, Cystic, Mucinous, and Serous | en_US |
dc.subject | Endometrial Neoplasms | en_US |
dc.subject | Neoplasm Recurrence, Local | en_US |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | en_US |
dc.subject | Neoplasm Staging | en_US |
dc.subject | Hysterectomy | en_US |
dc.subject | Survival Rate | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Cohort Studies | en_US |
dc.subject | Aged | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | African Americans | en_US |
dc.subject | United States | en_US |
dc.subject | Female | en_US |
dc.subject | Electronic Health Records | en_US |
dc.subject | Kaplan-Meier Estimate | en_US |
dc.subject | Antineoplastic Agents, Immunological | en_US |
dc.subject | Whites | en_US |
dc.title | Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records. | en |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-12-04 | |
rioxxterms.version | VoR | en |
rioxxterms.versionofrecord | 10.1016/j.ygyno.2021.12.008 | en |
dc.relation.isPartOf | Gynecologic oncology | en_US |
pubs.issue | 2 | en_US |
pubs.notes | Not known | en_US |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | en_US |
pubs.volume | 164 | en_US |
pubs.embargo.terms | Not known | en_US |
dc.contributor.icrauthor | Banerjee, Susana | |